Literature DB >> 24284831

Impact of stereotactic body radiotherapy on colorectal cancer with distant metastases.

Masayuki Hiraki1, Junichi Nishimura1, Masahisa Ohtsuka1, Hiroya Shiomi2, Mamoru Uemura1, Naotsugu Haraguchi1, Taishi Hata1, Taro Hayashi3, Ichiro Takemasa1, Tsunekazu Mizushima1, Fumiaki Isohashi4, Yasuo Yoshioka4, Kazuhiko Ogawa4, Yuichiro Doki1, Masaki Mori1, Hirofumi Yamamoto1.   

Abstract

Stereotactic radiotherapy is a minimally invasive technique for delivering highly focused ionizing radiation with extreme precision. This technique was initially developed in neurosurgical practice and applied to extracranial lesions in the 1990s, and was termed stereotactic body radiotherapy (SBRT). Studies have reported that the resection of distant metastases from colorectal cancer (CRC) contributes to relatively long-term survival. However, the resection of pulmonary and liver metastases is not possible for various reasons. SBRT offers a therapeutic alternative to unresectable metastatic lesions. The present study describes three cases of distant metastasis from CRC that exhibited a complete response (CR) to SBRT. Case 1 is a 70-year-old man with recurrent liver metastases after surgery for rectal cancer with liver metastasis (S3: diameter 1.8 cm and volume 3.0 ml; S6: diameter 1.3 cm and volume 1.2 ml). Cases 2 and 3 were 65-year-old and 70-year-old men, respectively. Both patients had pulmonary metastasis after surgery for rectal and cecum cancer (Case 2: diameter 1.2 cm and volume 0.9 ml; Case 3: diameter 0.8 cm and volume 0.27 ml). All cases were moderately differentiated adenocarcinomas. No serious adverse side-effects were observed during the therapy. CR was obtained in all patients on the basis of computed tomography 15-33 months after radiotherapy. Our experience supports that SBRT is a safe and alternative technique for resection in patients with distant metastasis from CRC who have small metastatic tumor volume.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24284831     DOI: 10.3892/or.2013.2871

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  4 in total

1.  A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer.

Authors:  Charalampos S Floudas; Gagandeep Brar; Donna Mabry-Hrones; Austin G Duffy; Bradford Wood; Elliot Levy; Venkatesh Krishnasamy; Suzanne Fioravanti; Cecilia M Bonilla; Melissa Walker; Maria Pia Morelli; David E Kleiner; Seth M Steinberg; William D Figg; Tim F Greten; Changqing Xie
Journal:  Clin Colorectal Cancer       Date:  2019-07-02       Impact factor: 4.481

Review 2.  Liver-directed therapies in metastatic colorectal cancer.

Authors:  Margaret E Clark; Richard R Smith
Journal:  J Gastrointest Oncol       Date:  2014-10

3.  Neoadjuvant chemotherapy and radiotherapy followed by resection/ablation in stage IV rectal cancer patients with potentially resectable metastases.

Authors:  Rongzhen Li; Qiaoxuan Wang; Bin Zhang; Weiwei Xiao; Yuanhong Gao; Yan Yuan; Weihao Xie; Xiaoxue Huang; Chengjing Zhou; Shu Zhang; Shaoqing Niu; Hui Chang; Dongni Chen; Huikai Miao; Zhi Fan Zeng
Journal:  BMC Cancer       Date:  2021-12-14       Impact factor: 4.430

Review 4.  We need to bring R0 < 1 to treat cancer too.

Authors:  Devabhaktuni Srikrishna; Kris Sachsenmeier
Journal:  Genome Med       Date:  2021-07-26       Impact factor: 11.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.